The recommendations include new treatments for cancer and intraocular pressure and prevention of uncomplicated flu.
News
Uni of Exeter partners with MDC to accelerate academic medicines research
Medicines Discovery Catapult (MDC) will offer industry skills and discovery platforms
NIHR establishes new patient recruitment research centres
Research centres will accelerate development of late-stage research within NHS
EU secures 300 million doses of BioNTech, Pfizer’s COVID-19 vaccine
Agreement follows positive phase III data announcement
NICE green light for Cablivi in rare blood-clotting disorder
Treatment recommended for acquired thrombotic thrombocytopenic purpura
Mallinckrodt launches retrospective study for inhaled therapy in COVID-19
Study will collect real-world data on use of INOmax in COVID-19 patients
Russian says its ‘Sputnik V’ COVID-19 vaccine is 92% effective
Interim data analysis comes from phase III clinical trials in the Russian Federation
Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
JADE REGIMEN study investigated JAK1 inhibitor in moderate to severe atopic dermatitis
UCB acquires gene therapy specialist Handl Therapeutics
Company also announces new collaboration with Lacerta Therapeutics
ViiV’s long-acting HIV drug beats standard of care in prevention study
Study was ended early after drug hit primary endpoint
AbbVie’s Venclyxto gets NICE blood cancer backing
Oral B-cell lymphoma-2 inhibitor approved to treat chronic lymphocytic leukaemia
Amgen, AZ’s asthma drug tezepelumab scores phase III win
Detailed results are due to be presented at forthcoming medical meeting
FDA grants emergency authorisation to Lilly’s COVID-19 antibody
Bamlanivimab approved for high-risk COVID-19 patients
UK study will evaluate aspirin as a potential COVID-19 treatment
RECOVERY study will assess if drug can reduce risk of blood clots
EU OK for AZ’s Calquence in CLL
BTK inhibitor approved based on results from two phase III trials
